Aziz Sheikh
Editor-in-Chief at Primary Care Respiratory Medicine
Contributor at PLOS
Professor @EdinburghUni
Articles
-
Jan 16, 2025 |
nature.com | Aziz Sheikh |Andrew JHL Snelling
AbstractSotrovimab is a neutralising monoclonal antibody (nMAB) currently available to treat extremely clinically vulnerable COVID-19 patients in England. Trials have shown it to have mild to moderate side effects, however, evidence regarding its safety in real-world settings remains insufficient.
-
Nov 27, 2024 |
nature.com | Luke Daines |Anne Canny |Eddie Donaghy |David Price |Frances S. Mair |Aziz Sheikh | +2 more
AbstractThere is uncertainty about how best to diagnose asthma, especially in primary care where mis-diagnosis is common. To address this, we developed a clinical decision support system (CDSS) for asthma diagnosis in children and young people (aged 5-25 years). This study explored the feasibility and acceptability of the CDSS in UK primary care. We recruited general practices from England and Scotland. The CDSS was available for use during routine consultations for six months.
-
Aug 13, 2024 |
nature.com | Stuart Bedston |Gavin M Jamie |Chris Robertson |Ashley Akbari |Aziz Sheikh |Xinchun Gu
AbstractVaccines against COVID-19 and influenza can reduce the adverse outcomes caused by infections during pregnancy, but vaccine uptake among pregnant women has been suboptimal. We examined the COVID-19 and influenza vaccine uptake and disparities in pregnant women during the COVID-19 pandemic to inform vaccination interventions.
-
Jul 8, 2024 |
nature.com | Emma Copland |Defne Saatci |Nicholas L. Mills |Paul Moss |Aziz Sheikh |Chris Robertson
Correction to: Nature Communications https://doi.org/10.1038/s41467-024-47745-z, published online 27 May 2024The original version of this article contained information on vaccine dose amount (full or half) in Table 2 and Supplementary Table 1. This has subsequently been found to be inaccurate due to inconsistent coding in the raw data. The vaccine dose amount has therefore been removed from Table 2 and Supplementary Table 1. This data was not used elsewhere in the analysis.
-
Jun 13, 2024 |
nature.com | Calum Macdonald |Norah E Palmateer |Laura Lindsay |Safraj Shahul Hameed |Karen Jeffrey |Luke Daines | +9 more
AbstractSeveral population-level studies have described individual clinical risk factors associated with suboptimal antibody responses following COVID-19 vaccination, but none have examined multimorbidity. Others have shown that suboptimal post-vaccination responses offer reduced protection to subsequent SARS-CoV-2 infection; however, the level of protection from COVID-19 hospitalisation/death remains unconfirmed.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 2K
- Tweets
- 1K
- DMs Open
- No
RT @RESPIREGlobal: Join an interactive discussion on engaging with policymakers with @zfrmrza & @DrAzizSheikh 🗓️Monday 12 February, 11.30 (…
RT @Dr_Ting_Shi: Fully funded PhD project based at Edinburgh, developing and validating a machine learning-based tool to predict respirator…
RT @EdinUniUsher: We are delighted to announce the appointment of Professor Julie Jacko as our new Co-Head of the Centre for Medical Inform…
